Apobiologix, a division of Apotex Inc., expanded its product portfolio with the launch of a pre-filled autoinjector for Lapelga®, the company’s biosimilar pegfilgrastim that launched in Canada in 2019. Apobiologix, focused on the development of biosimilars for global markets, is the only biosimilar company to offer a pegfilgrastim autoinjector. The pre-filled syringe for Lapelga will continue to be available to patients.